This product is a prodrug of acyclovir. It is rapidly absorbed after oral administration and quickly converted into acyclovir in the body. Its antiviral effect is exerted by acyclovir. After acyclovir enters the herpes infected cells, it competes with deoxynucleoside for viral thymidine kinase or cellular kinase. The drug is phosphorylated into activated acyclosine triphosphate, which competes with deoxyguanine triphosphate for viral DNA polymerase as a substrate for viral replication, thereby inhibiting viral DNA synthesis and showing antiviral effect. The antiviral activity of this product in vivo is better than that of acyclovir, and the therapeutic index for herpes simplex virus type I and type II is 42.91% and 30.13% higher than that of acyclovir, respectively. It also has a high efficacy against varicella zoster virus and has very low toxicity to mammalian host cells.

Extract from the above information

It can reduce the increase of serum AST and ALT in the animal acute liver injury model caused by TAA (thioacetamide) and CC14 (carbon tetrachloride), and inhibit the accumulation of triglycerides caused by chronic liver injury model; it can promote liver glycogen synthesis, inhibit the increase of cholesterol, and help the serum albumin/globulin ratio to rise

It can reduce the increase of serum AST and ALT in the animal acute liver injury model caused by TAA (thioacetamide) and CC14 (carbon tetrachloride), and inhibit the accumulation of triglycerides caused by chronic liver injury model; it can promote liver glycogen synthesis, inhibit the increase of cholesterol, and help to restore the serum albumin/globulin ratio.

This product can reduce capillary permeability, enhance the retraction effect of broken capillary ends, and increase the resistance of capillaries to damage. It is often used for various types of bleeding caused by increased capillary permeability.